Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemarituzumab + anlotinib + etoposide + carboplatin followed by thoracic radiotherapy for extensive-stage small cell lung cancer (Phase II, single-arm)
ChiCTR2500110390Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Guangdong Medical University
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bemarituzumab in small cell lung cancer (SCLC), sponsored by The Affiliated Hospital of Guangdong Medical University. Primary endpoints: Overall survival (OS) and Progression-free survival (PFS). Planned start Oct 2025; status: not yet recruiting.
02
Drugs
bemarituzumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500110390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110390.